E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Atherosclerosis in the carotids and coronary arteries. |
Atherosclerose in de carotiden en coronairen. |
|
E.1.1.1 | Medical condition in easily understood language |
Atherosclerosis in the carotid- and coronary arteries. |
Aderverkalking in de grote halsslagaders en kransslagaders. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cardiovascular Diseases [C14] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To validate 18F-Flutemetamol PET in the evaluation of plaque vulnerability. |
18F-Flutemetamol valideren als PET-tracer voor de evaluatie van 'plaque vulnerability'. |
|
E.2.2 | Secondary objectives of the trial |
To explore a possible relation between tracer uptake in the carotids and cognitive symptoms or radiological characteristics of (early) dementia. |
Om een mogelijke relatie tussen traceropname in de carotiden met cognitieve klachten of radiologische afwijkingen suspect voor (beginnende) dementie te exploreren. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Age 18 years and older (no maximum age) Informed consent by signed informed consent form regarding this study Either: Patients, who are scheduled for carotid endarterectomy (CEA) Or: Patients who are not scheduled to undergo a CEA, but have experienced a TIA/CVA/amaurosis fugax within the last 14 days and at least a 30% stenosis of the symptomatic carotid artery as based on flow velocities with duplex ultrasonography. |
Leeftijd van 18 jaar of ouder (geen maximum leeftijd) Getekend informed consent formulier van de betreffende studie. Ofwel: patiënten die gepland staan voor een carotisendarteriëctomie (CEA). Ofwel: patiënten die niet gepland zijn voor deze procedure, maar die wel in de afgelopen 14 dagen een TIA/CVA/amaurosis fugax hebben gehad en bij duplex onderzoek een stenose van de symptomatische carotis hadden van tenminste 30%. |
|
E.4 | Principal exclusion criteria |
Severe cognitive impairment, neurological deficit or comorbidity causing the study to be too high a burden for the patient or disrupting patient’s co-operation with scan procedures. Evident other causality for stroke (cardiac embolus, small vessel disease, carotid dissection or thrombogenic diathesis). Pregnant women and nursing mothers. Contra-indications for MRI. ď‚§Relative contra-indications for MRI-contrast agent: GFR <30ml/min/1,73m2/Previous allergic reaction to MRI contrast agent. Contra-indication Flutemetamol: Hypersensitivity to the active substance or to any of the excipients |
Ernstige cognitieve klachten, neurologische uitval of comorbiditeit, waardoor het onderzoek als té belastend wordt ervaren of waardoor de patiënt onvoldoende mee kan werken. Evident andere oorzaak van de beroerte (cardiale emboliebron, 'small vessel disease', dissectie, stollingsstoornis) Vrouwen die (mogelijk) zwanger zijn of borstvoeding geven. Contra-indications for MRI. ď‚§Relatieve contra-indications for MRI-contrastmiddel: GFR <30ml/min/1,73m2 / Eerdere allergische reactie op MRI-contrastmiddel. Contra-indicaties Flutemetamol: Overgevoeligheid voor de actieve stof of hulpstoffen. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Target-to-background-ratio in the symptomatic carotid artery plaque. |
'Target-to-background-ratio' in de symptomatische carotis plaque. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
After 25 patients. |
Na 25 patiënten. |
|
E.5.2 | Secondary end point(s) |
MRI and (when available) histologic measures of plaque vulnerability characteristics. Tracer uptake in the coronary arteries |
MRI en (zo mogelijk) histologische maten van 'kwetsbare-plaque-kenmerken'. Stapeling van de tracer in de coronairen. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
After 25 patients. |
Na 25 patiënten. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | Yes |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 9 |
E.8.9.1 | In the Member State concerned days | 0 |